Rilexine 75 mg Tablets for Dogs and Cats

País: Reino Unido

Língua: inglês

Origem: VMD (Veterinary Medicines Directorate)

Ingredientes ativos:

Cefalexin

Disponível em:

Virbac

Código ATC:

QJ01DB01

DCI (Denominação Comum Internacional):

Cefalexin

Forma farmacêutica:

Tablet

Tipo de prescrição:

POM-V - Prescription Only Medicine – Veterinarian

Grupo terapêutico:

Cats, Dogs

Área terapêutica:

Antimicrobial

Status de autorização:

Authorized

Data de autorização:

2005-10-24

Características técnicas

Revised: December 2022
AN: 02162/2022
Page 1 of 6
SUMMARY OF THE PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Rilexine 75 mg Tablets for dogs and cats
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
One tablet contains:
-Active substance
Cefalexin …………………………………………….75 mg
(as Cefalexin Monohydrate)
For the full list of excipients see section 6.1.
3. PHARMACEUTICAL FORM
Tablets.
Creamy oblong tablets with small brown spots with a score-line.
The tablets can be divided into halves.
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of bacterial skin infections in dogs (including deep
and superficial
pyodermas) caused by organisms susceptible to Cefalexin.
For the treatment of cutaneous and subcutaneous infections (wounds and
abscesses) in
cats caused by organisms susceptible to Cefalexin.
For the treatment of urinary-tract infections in cats and dogs
(including nephritis and
cystitis) caused by organisms susceptible to Cefalexin.
4.3 CONTRA-INDICATIONS
Do
not
use
in
animals
which
are
known
to
be
hypersensitive
to
penicillins
and
cephalosporins.
Do not use in rabbits, guinea pigs, hamsters and gerbils.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Revised: December 2022
AN: 02162/2022
Page 2 of 6
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
As
with
other
antibiotics
which
are
excreted
mainly
by
the
kidneys,
unnecessary
accumulation may occur in the body when renal function is impaired. In
case of known
renal
insufficiency,
the
dose
should
be
reduced
and
antimicrobials
known
to
be
nephrotoxic should not be administered concurrently.
This product should not be used to treat puppies of less than 1 kg of
bodyweight or kittens
under 9 weeks of age.
Use of the product deviating from the instructions given in the S.P.C.
may increase the
prevalence of bacteria resistant to Cefalexin and may decrease the
effectiveness of
treatment
with
other
cephalosporins
and
peni